The 2023 win­ners and losers list: Who was up and who was down in bio­phar­ma

I hate end-of-the-year pieces. They tend to be dull and as­signed by some ed­i­tor who sees the odome­ter rolling over and thinks that’s more in­ter­est­ing than ac­tu­al news.

But part of the gig at End­points News is keep­ing tabs on who’s ⬆️ and who’s ⬇️, which strate­gies and mech­a­nisms are pay­ing off (and which are fail­ing), and what it says about the fu­ture for the com­pa­nies, ideas, mol­e­cules, in­vest­ments and peo­ple we fol­low every day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER